Linked Life Data

17390039

Source:http://linkedlifedata.com/resource/pubmed/id/17390039

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2007-3-28
pubmed:abstractText
The sensitivity of LN metastases to anticancer drugs such as CPT-11 and platinum agents was investigated by assessing Topo-1 and Bax/ERCC-1 expression in patients who had stage III/Dukes' C colorectal cancer with ONCs. In the recurrence group (RG) (n=21), immunohistochemical expression of Topo-1 was high in 8 patients (38.1%), and low in 13 patients (61.9%), while the non-recurrence group (N-RG) (n=12) showed high expression in 1 patient (8.3%) and low expression in 11 patients (91.7%) (not significant; N.S.). Regarding the immunohistochemical expression of Bax/ERCC-1, high Bax/low ERCC-1 expression was observed in 6 patients (28.6%) from the RG and other patterns of expression were seen in 15 patients (71.4%), while high Bax/low ERCC-1 expression level was observed in 3 patients (25.0%) from the N-RG and other patterns were found in 9 patients (75.0%) (N.S.). PCR analysis of Topo-1 expression in the RG (n=13) revealed high expression in 10 patients (76.9%) and low expression in 3 patients (23.1%), while the N-RG (n=3) showed high expression in 3 patients (100%) and low expression in none (N.S.). With respect to ERCC-1, PCR analysis of the RG (n=13) revealed high expression in 6 patients (46.2%) and low expression in 7 patients (53.8%), while the N-RG (n=3) showed high expression in 2 patients (66.7%) and low expression in 1 patient (33.3%) (N.S.). These results suggest that tumor sensitivity to CPT-11 and platinum derivatives is similar in stage III colorectal cancer patients with ONCs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1021-335X
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1027-32
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17390039-Camptothecin, pubmed-meshheading:17390039-Colorectal Neoplasms, pubmed-meshheading:17390039-DNA Topoisomerases, Type I, pubmed-meshheading:17390039-DNA-Binding Proteins, pubmed-meshheading:17390039-Endonucleases, pubmed-meshheading:17390039-Humans, pubmed-meshheading:17390039-Immunohistochemistry, pubmed-meshheading:17390039-Lymph Nodes, pubmed-meshheading:17390039-Lymphatic Metastasis, pubmed-meshheading:17390039-Neoplasm Recurrence, Local, pubmed-meshheading:17390039-Neoplasm Staging, pubmed-meshheading:17390039-Neoplasms, Unknown Primary, pubmed-meshheading:17390039-Organoplatinum Compounds, pubmed-meshheading:17390039-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17390039-Topoisomerase I Inhibitors, pubmed-meshheading:17390039-bcl-2-Associated X Protein
pubmed:year
2007
pubmed:articleTitle
Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
pubmed:affiliation
Tokai University Hachioji Hospital, Department of Surgery, Tokyo 192-0032, Japan. mukai.masaya@hachioji-hosp.tokai.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't